Carilzomib Alone Not Effective for Refractory Multiple Myeloma

Share this content:

the Cancer Therapy Advisor take:

Amgen has announced disappointing results from their phase 3 study, Carfilzomib for Advanced Refractory Multiple Myeloma European Study (FOCUS) as carfilzomib (Kyprolis) did not reach its primary endpoint for the treatment of refractory multiple myeloma.

 

The phase 3, open-label study assessed carfilzomib versus a regimen of low-dose dexamethasone plus optional cyclophosphamide for the treatment of patients with multiple myeloma who have received at least three prior therapies.

 

The study, which included 315 patients, showed that carfilzomib did not improve overall survival, their primary endpoint. Secondary endpoints consisted of clinical benefit rate, duration of response, overall response rate, progression-free survival, and safety. The study demonstrated an increased risk of nephrotoxicity in those that were randomized to carfilzomib.

 

Despite the setback, Amgen is optimistic that it will receive approval for its drug based on the positive phase 3 ASPIRE study, which evaluated the efficacy and safety of carfilzomib plus lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma.

 

Kyprolis, a selective proteasome inhibitor, was granted accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with multiple myeloma who have received at least two prior treatments, including bortezomib and an immunomodulatory agent.

Carilzomib Alone Not Effective for Refractory Multiple Myeloma
Amgen suffered a major setback when FOCUS did not meet its primary endpoint.

Amgen (AMGN) suffered a major setback when its phase III study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.

The open-label study evaluated Kyprolis versus an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients suffering from relapsed and advanced refractory multiple myeloma.

However, the study did not meet its primary endpoint of improving overall survival (:OS). The results from the study showed that there was an increase in the incidence of renal adverse events of all grades in the Kyprolis arm compared to the active control arm and the label.

READ FULL ARTICLE From Yahoo News

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs